Table 1.

Patients’ characteristics

UPN	Diagnosis	Disease status	Light chain isotype	Cytogenetics	ISS stage	Therapy at sampling	Clinical status*
1	MM	Relapse	IgG κ	Normal	III	PDN, Cy	Deceased
2	SMM	Onset	IgG λ	t(4;14)	N.A.	None	Alive/SMM
3	MM	Stable disease	Non secretory	Normal	I	None	Alive/PR
4	SMM	Onset	IgA κ	Normal	N.A.	None	Alive/SMM
5	MM	Partial response	IgG κ	Normal	I	PDN, Thalidomide	Alive/PR
6	MM	Onset	IgG κ	Del(13q); t(4;14)	I	None	Deceased
7	MM	Onset	IgA λ	Normal	III	None	Lost at follow-up
8	MM	Onset	IgG λ	Del(13q)	I	None	Alive/PR
9	MM	Onset	IgD λ	Del(13q)	I	VMPT	Alive/CR
10	MGUS	--	Micromolecular, λ	Normal	N.A.	None	Alive/MGUS
11	MM	Onset	Micromolecular, κ	Normal	I	Prednisone	Alive/Stable disease
12	MGUS	--	IgG κ	Normal	N.A.	None	Alive/MGUS
13	MM	Onset	Micromolecular, κ	Normal	III	Auto-HSCT	Alive/CR
14	MM	Relapse	IgA κ	Del(13q)	I	Prednisone	Alive/PD
15	MM	Onset	NA	Normal	II	None	NA
16	MM	Partial response	IgG λ	Normal	III	PDN	Alive/Stable disease
17	MM	Relapse	IgA λ	Normal	III	PDN	Alive/PR
18	SMM	Onset	IgA κ	Normal	N.A.	None	Alive/progressed to MM
19	MM	Relapse	IgA κ	p53 mutation	II	None	Alive/PR
20	MM	Stable disease	IgG κ	Normal	I	MP	Deceased
21	SMM	Onset	IgG λ	Normal	N.A.	None	Alive/SMM
22	MGUS	--	IgG κ	Normal	N.A.	None	Alive/MGUS
23	MM	Onset	IgG κ	t(11;14);14q32 translocation	I	None	Alive
24	MM	Onset	IgG κ	Del(13q); del(17p)	II	None	Alive
25	MM	Relapse	IgA	Del(13q); t(4:14)	II	None	Alive, relapse
26	MM	Onset	Micromolecular, λ	ND	III	None	Alive/PR
27	MM	Relapse	Non secretory	ND	I	None	Alive/VGPR
28	MM	Relapse	IgA λ	Normal	I	None	Alive/VGPR
29	MM	Onset	IgA κ	Del(13q); del(17p)	III	None	Alive/PD
30	MM	Onset	IgA λ	Del(13q); t(4:14)	I	None	Alive/PR
31	MM	Relapse	IgG κ	ND	I	Prednisone	Alive/PD
32	MM	Relapse	IgG κ	ND	I	None	Alive/PR

Patients’ characteristics. Patients’ demographics, disease features, medical therapies and disease status at sampling are shown. Abbreviations: SMM smoldering multiple myeloma, CR complete remission, PR partial remission, PD progressive disease, VGPR very good partial response, NA not applicable, ND not done, BJ Bence-Jones proteinuria. PDN prednisone, Cy cyclophosphamide, MP melphalan + prednisone, VMPT bortezomib, melphalan, prednisone and thalidomide

*12 months after inclusion in the study.